Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...

Besides the earnings beat, the drugmaker announced another bit of good news that also had the market excited. Regeneron is now a dividend-paying company. The stock has lagged the market over the last ...

It’s true: old dogs can learn new tricks — and we’re proof of that! I’m Lilly, an affectionate golden girl, here with my ...

The Parnassus Growth Equity Fund returned 4.85% (net) for Q4 2024, underperforming the Russell 1000 Growth Index’s 7.07%.

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are two important insights from that call that should excite investors about ...

In total, 234 investments creating 13,500 new jobs over the next five years, 59% of which were in regional locations ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co.